Maravai LifeSciences Holdings Inc. Class A Common Stock vs Paycom Software Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Paycom Software Inc trades at $238.6 (market cap $10.67B). The key difference: Paycom Software Inc is far larger — about 11× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Paycom Software Inc pays a 0.63% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Paycom Software Inc for 84 Days on average.
| MRVI | PAYC | |
|---|---|---|
Market Cap | $972.90M | $10.67B |
Volume | 4,325,710 | 411,289 |
Sector | Health | Technology |
52-Week High | $9.00 | $240.52 |
52-Week Low | $2.83 | $113.59 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $1.08B | $11.45B |
Dividend Yield | — | 0.63% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
PAYC trades at $239.00, up 1.7% today, with a bullish technical trend and strong fundamentals. The company reported Q2 2026 EPS of $2.78, beating estimates by 17%, and raised full-year guidance to 7-8% revenue growth. Valuation metrics show a P/E of 25.04 and robust profitability with a net margin of 22.78%. Recent news highlights institutional buying and positive earnings momentum.
The outlook is positive given earnings beats and raised guidance, but risks include high valuation multiples and competitive pressures. Analysts are mixed with a $211.08 consensus target, below the current price, suggesting cautious optimism. The stock's proximity to its 52-week high warrants monitoring for pullbacks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →